{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:01:32Z","timestamp":1783033292874,"version":"3.54.6"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40256-025-00781-6","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:40:58Z","timestamp":1765881658000},"page":"225-232","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Role of Sodium\u2013Glucose Cotransporter 2 Inhibitors in Patients with Sarcoid Cardiomyopathy: A Multicenter Retrospective Cohort Study"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9729-9961","authenticated-orcid":false,"given":"Ahmed K.","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohab","family":"Elnashar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abdelnabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang Nhat","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Tiseer","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Patten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"issue":"2","key":"781_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.31083\/j.rcm2502037","volume":"25","author":"A Vereckei","year":"2024","unstructured":"Vereckei A, Besenyi Z, Nagy V, Radics B, Vago H, Jenei Z, et al. Cardiac sarcoidosis: a comprehensive clinical review. Rev Cardiovasc Med. 2024;25(2):37.","journal-title":"Rev Cardiovasc Med"},{"issue":"10","key":"781_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2021.100936","volume":"46","author":"AC Alba","year":"2021","unstructured":"Alba AC, Gupta S, Kugathasan L, Ha A, Ochoa A, Balter M, et al. Cardiac sarcoidosis: a clinical overview. Curr Probl Cardiol. 2021;46(10):100936.","journal-title":"Curr Probl Cardiol"},{"issue":"2","key":"781_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","volume":"5","author":"KM Talha","year":"2023","unstructured":"Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: a review of current evidence. Int J Heart Fail. 2023;5(2):82\u201390.","journal-title":"Int J Heart Fail."},{"issue":"5","key":"781_CR4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11897-021-00529-8","volume":"18","author":"S Pabel","year":"2021","unstructured":"Pabel S, Hamdani N, Luedde M, Sossalla S. SGLT2 inhibitors and their mode of action in heart failure-has the mystery been unravelled? Curr Heart Fail Rep. 2021;18(5):315\u201328.","journal-title":"Curr Heart Fail Rep"},{"issue":"18","key":"781_CR5","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895\u20131032.","journal-title":"Circulation"},{"issue":"2","key":"781_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"MB Palchuk","year":"2023","unstructured":"Palchuk MB, London JW, Perez-Rey D, Drebert ZJ, Winer-Jones JP, Thompson CN, et al. A global federated real-world data and analytics platform for research. JAMIA Open. 2023;6(2):ooad035.","journal-title":"JAMIA Open"},{"key":"781_CR7","unstructured":"https:\/\/trinetx.com\/."},{"issue":"5","key":"781_CR8","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","volume":"29","author":"MB Mathur","year":"2018","unstructured":"Mathur MB, Ding P, Riddell CA, VanderWeele TJ. Web site and R package for computing E-values. Epidemiology. 2018;29(5):e45\u20137.","journal-title":"Epidemiology"},{"issue":"4","key":"781_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"issue":"1","key":"781_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, Li X, Han F, Liu X, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"781_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29486","volume":"10","author":"J Hu","year":"2024","unstructured":"Hu J, Teng J, Hui S, Liang L. SGLT-2 inhibitors as novel treatments of multiple organ fibrosis. Heliyon. 2024;10(8):e29486.","journal-title":"Heliyon."},{"key":"781_CR12","doi-asserted-by":"crossref","unstructured":"Rykova EY, Klimontov VV, Shmakova E, Korbut AI, Merkulova TI, Kzhyshkowska J. Anti-inflammatory effects of SGLT2 inhibitors: focus on macrophages. Int J Mol Sci. 2025;26(4):1670.","DOI":"10.3390\/ijms26041670"},{"issue":"1","key":"781_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cardfail.2021.06.016","volume":"28","author":"NA Gilotra","year":"2022","unstructured":"Gilotra NA, Griffin JM, Pavlovic N, Houston BA, Chasler J, Goetz C, et al. Sarcoidosis-related cardiomyopathy: current knowledge, challenges, and future perspectives state-of-the-art review. J Card Fail. 2022;28(1):113\u201332.","journal-title":"J Card Fail"},{"issue":"21","key":"781_CR14","doi-asserted-by":"publisher","first-page":"e1197","DOI":"10.1161\/CIR.0000000000001240","volume":"149","author":"RK Cheng","year":"2024","unstructured":"Cheng RK, Kittleson MM, Beavers CJ, Birnie DH, Blankstein R, Bravo PE, et al. Diagnosis and management of cardiac sarcoidosis: a scientific statement from the American Heart Association. Circulation. 2024;149(21):e1197\u2013216.","journal-title":"Circulation"},{"key":"781_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.915455","volume":"9","author":"J Wu","year":"2022","unstructured":"Wu J, Liu Y, Wei X, Zhang X, Ye Y, Li W, et al. Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: a mini review. Front Cardiovasc Med. 2022;9:915455.","journal-title":"Front Cardiovasc Med"},{"key":"781_CR16","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3389\/fphys.2020.00912","volume":"11","author":"X Peng","year":"2020","unstructured":"Peng X, Li L, Zhang M, Zhao Q, Wu K, Bai R, et al. Sodium-glucose cotransporter 2 inhibitors potentially prevent atrial fibrillation by ameliorating ion handling and mitochondrial dysfunction. Front Physiol. 2020;11:912.","journal-title":"Front Physiol"},{"issue":"21","key":"781_CR17","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"781_CR18","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"2","key":"781_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"12","key":"781_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"3","key":"781_CR21","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jacasi.2022.03.009","volume":"2","author":"Y Kubota","year":"2022","unstructured":"Kubota Y, Shimizu W. Clinical benefits of sodium-glucose cotransporter 2 inhibitors and the mechanisms underlying their cardiovascular effects. JACC Asia. 2022;2(3):287\u201393.","journal-title":"JACC Asia"},{"issue":"1","key":"781_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42444-024-00109-6","volume":"25","author":"A Paul","year":"2024","unstructured":"Paul A, Tabaja C, Wazni O. SGLT2 inhibitors and the cardiac rhythm: unraveling the connections. Int J Arrhythm. 2024;25(1):2.","journal-title":"Int J Arrhythm"},{"issue":"7","key":"781_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218919","volume":"14","author":"F Cozzolino","year":"2019","unstructured":"Cozzolino F, Montedori A, Abraha I, Eusebi P, Grisci C, Heymann AJ, et al. A diagnostic accuracy study validating cardiovascular ICD-9-CM codes in healthcare administrative databases. The Umbria Data-Value Project. PLoS ONE. 2019;14(7):e0218919.","journal-title":"PLoS ONE"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00781-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00781-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00781-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:24:02Z","timestamp":1771507442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00781-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00781-6","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ahmed K. Mahmoud, Ibrahim Kamel, Kamal Awad, Mohab Elnashar, Ahmed Younes, Juan Farina, Ramzi Ibrahim, Mahmoud Abdelnabi, Mohamed Allam, Hoang Nhat Pham, Mohammed Tiseer Abbas, Chadi Ayoub, Reza Arsanjani, and Richard D. Patten declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data are publicly available in the TriNetX Database through institutional agreement.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.K.M.: conceptualization, methodology, data curation, analysis, visualization, writing, and reviewing and editing. I.K.: data curation, analysis, and writing. K.A.: methodology, validation, and reviewing and editing. M.E.: data curation, visualization, and investigation. A.Y.: methodology, investigation, and reviewing and editing. J.F.: supervision, validation, and reviewing and editing. R.I.: validation, analysis, and reviewing and editing. M.A. (Mahmoud Abdelnabi): methodology, validation, and reviewing and editing. M.A. (Mohamed Allam): resources, validation, and project administration. H.N.P.: software, analysis, and visualization. M.T.A.: project administration, data curation, and resources. C.A.: conceptualization, supervision, and reviewing and editing. R.A.: supervision, validation, and final manuscript approval. R.D.P.: supervision, reviewing and editing, and final manuscript approval.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}